GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Peak Bio Inc (OTCPK:PKBO) » Definitions » EV-to-EBITDA

Peak Bio (Peak Bio) EV-to-EBITDA : -0.36 (As of May. 27, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Peak Bio EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Peak Bio's enterprise value is $8.47 Mil. Peak Bio's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 was $-23.29 Mil. Therefore, Peak Bio's EV-to-EBITDA for today is -0.36.

The historical rank and industry rank for Peak Bio's EV-to-EBITDA or its related term are showing as below:

PKBO' s EV-to-EBITDA Range Over the Past 10 Years
Min: -12.5   Med: -0.9   Max: -0.36
Current: -0.36

During the past 2 years, the highest EV-to-EBITDA of Peak Bio was -0.36. The lowest was -12.50. And the median was -0.90.

PKBO's EV-to-EBITDA is ranked worse than
100% of 451 companies
in the Biotechnology industry
Industry Median: 9.67 vs PKBO: -0.36

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-27), Peak Bio's stock price is $0.0086. Peak Bio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was $-1.306. Therefore, Peak Bio's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Peak Bio EV-to-EBITDA Historical Data

The historical data trend for Peak Bio's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Peak Bio EV-to-EBITDA Chart

Peak Bio Annual Data
Trend Dec21 Dec22
EV-to-EBITDA
- -7.28

Peak Bio Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
EV-to-EBITDA Get a 7-Day Free Trial - - -7.28 -0.99 -1.10

Competitive Comparison of Peak Bio's EV-to-EBITDA

For the Biotechnology subindustry, Peak Bio's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Peak Bio's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Peak Bio's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Peak Bio's EV-to-EBITDA falls into.



Peak Bio EV-to-EBITDA Calculation

Peak Bio's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=8.467/-23.29
=-0.36

Peak Bio's current Enterprise Value is $8.47 Mil.
Peak Bio's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-23.29 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Peak Bio  (OTCPK:PKBO) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Peak Bio's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.0086/-1.306
=At Loss

Peak Bio's share price for today is $0.0086.
Peak Bio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.306.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Peak Bio EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Peak Bio's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Peak Bio (Peak Bio) Business Description

Traded in Other Exchanges
N/A
Address
4900 Hopyard Road, Suite 100, Pleasanton, CA, USA, 94588
Peak Bio Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics addressing unmet needs in the areas of oncology and inflammation.
Executives
Hoyoung Huh director C/O NEKTAR THERAPEUTICS, 201 INDUSTRIAL ROAD, SAN CARLOS CA 94070
Michael R. Friedman director 245 E. 58TH STREET, APT #15B, NEW YORK NY 10022
Peter David Mccabe officer: General Counsel 584 CASTRO STREET, #882, SAN FRANCISCO CA 94114
Sbi Kis 2016-1 Fund 10 percent owner 14TH FL., NC TOWER, 509, TEHERAN-RO GANGNAM, SEOUL M5 00000
2014 Kif-sbi It Investment Fund 10 percent owner 14TH FL., NC TOWER, 509, TEHERAN-RO, GANGNAM, SEOUL M5 00000
2019 Sbi Job Creation Fund 10 percent owner 14TH FL., NC TOWER, 509, TEHERAN-RO, GANGNAM, SEOUL M5 00000
Sbi Investment Korea Co., Ltd. 10 percent owner 14TH FL., NC TOWER, 509, TEHERAN-RO, GANGNAM, SEOUL M5 00000
Sbi Healthcare Fund I 10 percent owner 14TH FL., NC TOWER, 509, TEHERAN-RO, GANGNAM, SEOUL M5 00000
Sbi Cross-border Advantage Fund 10 percent owner 14TH FL., NC TOWER, 509, TEHERAN-RO, GANGNAM, SEOUL M5 00000
Bio Fund 1 Ikbc-sbi 10 percent owner 14TH FL., NC TOWER, 509, TEHERAN-RO, GANGNAM, SEOUL M5 00000
Gateway Fund 1 Global 10 percent owner 14TH FL., NC TOWER, 509, TEHERAN-RO, GANGNAM, SEOUL M5 00000
Nevan C Elam director C/O NEKTAR THERAPEUTICS, 150 INDUSTRIAL ROAD, SAN CARLOS CA 94070
Satyajit Kumar Mitra officer: See Remarks 3350 W BAYSHORE ROAD, SUITE 100, PALO ALTO CA 94303
Stephen J Lamond director, officer: See Remarks 3350 W BAYSHORE ROAD, SUITE 100, PALO ALTO CA 94303
David I. Rosenberg director C/O IGNYTE ACQUISITION CORP., 640 5TH AVENUE, 4TH FLOOR, NEW YORK NY 10019